Payment overview · 2025
General Payments
$154.07
9 reported records · 7 companies
Healthcare provider profile · identity verified
Mark A Peterson, MD
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, AR · NPI 1407810898
Verified facts
What the public records show
CMS Open Payments records show Mark A Peterson, MD received $154.07 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.72 | 30.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.01 | 18.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.81 | 10.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.50 | 10.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.92 | 10.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.28 | 9.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.83 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.07 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.72 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.30 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
209 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 534 | 144 |
| Gabapentin | Gabapentin | 528 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 527 | 132 |
| Omeprazole | Omeprazole | 329 | 82 |
| Allopurinol | Allopurinol | 320 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 300 | 47 |
| Losartan Potassium | Losartan Potassium | 292 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 58 |
| Metformin Hcl | Metformin Hcl | 214 | 63 |
| Ozempic | Semaglutide | 209 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 63 |
| Tramadol Hcl | Tramadol Hcl | 192 | 62 |
| Trazodone Hcl | Trazodone Hcl | 191 | 52 |
| Simvastatin | Simvastatin | 190 | 49 |
| Lisinopril | Lisinopril | 189 | 52 |
| Bupropion Hcl Sr | Bupropion Hcl | 169 | 44 |
| Celecoxib | Celecoxib | 164 | 42 |
| Clonazepam | Clonazepam | 141 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 22 |
| Potassium Chloride | Potassium Chloride | 136 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 132 | 26 |
| Cefuroxime | Cefuroxime Axetil | 124 | 86 |
| Alprazolam | Alprazolam | 122 | 23 |
| Famotidine | Famotidine | 122 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 121 | 38 |
| Lovastatin | Lovastatin | 120 | 34 |
| Pregabalin | Pregabalin | 115 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 39 |
| Ondansetron Odt | Ondansetron | 107 | 48 |
| Glipizide | Glipizide | 105 | 30 |
| Sertraline Hcl | Sertraline Hcl | 100 | 28 |
| Spironolactone | Spironolactone | 98 | 33 |
| Furosemide | Furosemide | 96 | 33 |
| Rizatriptan | Rizatriptan Benzoate | 95 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 19 |
| Finasteride | Finasteride | 89 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 14 |
| Prednisone | Prednisone | 78 | 63 |
| Mounjaro | Tirzepatide | 76 | suppressed |
| Azithromycin | Azithromycin | 74 | 56 |
| Ibuprofen | Ibuprofen | 74 | 25 |
| Atenolol | Atenolol | 72 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 22 |
| Meloxicam | Meloxicam | 72 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 15 |
| Montelukast Sodium | Montelukast Sodium | 69 | 26 |
| Mirtazapine | Mirtazapine | 68 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 16 |
| Metformin Hcl Er | Metformin Hcl | 63 | 15 |
| Mupirocin | Mupirocin | 63 | 33 |
| Fluconazole | Fluconazole | 62 | 31 |
| Buspirone Hcl | Buspirone Hcl | 61 | 13 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 21 |
| Eliquis | Apixaban | 59 | 11 |
| Glimepiride | Glimepiride | 59 | 17 |
| Methocarbamol | Methocarbamol | 57 | 21 |
| Estradiol | Estradiol | 55 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 13 |
| Glipizide Er | Glipizide | 49 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 14 |
| Clonidine Hcl | Clonidine Hcl | 42 | 17 |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Valacyclovir | Valacyclovir Hcl | 41 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Naproxen | Naproxen | 37 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 16 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 32 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 15 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Imipramine Hcl | Imipramine Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 11 |
| Lidocaine | Lidocaine | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Cefprozil | Cefprozil | 18 | 15 |
| Risperidone | Risperidone | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 15 |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.07 · 9 records | Amgen Inc. | AIRSUPRA, CARDIOMEMS, Dexcom G6 Transmitter, MOUNJARO, OTEZLA, REPATHA, Wegovy, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error